TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Depressive Disorder, Major (SCID)~* HDRS \> 18~Exclusion Criteria:~* Other axis I disorders, including Bipolar Disorder, Schizophrenia, Substance Abuse Disorders.~* Any axis II disorders.~* Any serious/life-threatening axis III disorders, such as Congestive Heart Failure, Pulmonary Obstructive Chronic Disease, Active Neoplasia.~* Neurological diseases such as Stroke (and Post-Stroke Depression), Dementias and others.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sham stimulation / sertraline (Type: EXPERIMENTAL): In this arm, patients will receive sham stimulation and sertraline 50mg/day. In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation.
- Sham stimulation / placebo pill (Type: SHAM_COMPARATOR): Placebo pills are sugar pills having the same size and shape of the active pills.~In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation.
- Active stimulation / Sertraline (Type: EXPERIMENTAL): In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Patients will receive Sertraline 50mg/day.
- Active stimulation / placebo pill (Type: EXPERIMENTAL): In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Placebo pills are sugar pills having the same size and shape of the active pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women presenting for evaluation at MSKCC with biopsy proven primary IDC or ILC~* No prior therapy for IDC or ILC~* Clinical need for local disease staging with breast MR (Group A only)~* Clinical need for neoadjuvant chemotherapy (Group B only)~* Patients must provide written informed consent~Exclusion Criteria:~* Age \<21 years~* Men~* Pregnancy or lactation~* Patients who have already started treatment for the current malignancy~* Patients who cannot undergo PET scanning (i.e. because of weight limits)~* Patients who are known to have contraindication for MRI (e.g. metal implants)~* Patients may only participate in group #1 or group #2, but not both

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Local staging patients (Type: EXPERIMENTAL): Breast MR and FACBC PET/PEM will be scheduled within one week of each other. Breast MR is a standard clinical examination and will be performed as standard.
- Neoadjuvant chemotherapy patients (Type: EXPERIMENTAL): Baseline FACBC PET/PEM will be scheduled within 1 week of beginning neoadjuvant therapy. A repeat FACBC PET/PEM will be scheduled after the conclusion of neoadjuvant therapy, and before definitive surgical management.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willingness to provide informed consent to participation in the study~  * Male or female 18-65 years of age~ * Peripheral blood microfilaremia levels \>50 microfilaria/ml (treatment group 1)~ * No evidence of filarial infection by Mf and Circulating filarial antigen (CFA) testing (treatment group 2)~ * No history of taking anti-filarial medications in past 2 years~Exclusion Criteria:~Known chronic illness, e.g. tuberculosis, diabetes, renal insufficiency~* Anemia (Hb \<7 g/dl) by HemaCue~* Not willing or able to give informed consent for the study~* Onchocerciasis rapid test (Ov16) and/or skin snip positive for onchocerciasis~* Permanent disability that prevents or impedes study participation and/or comprehension Pregnancy. Women will be tested with a rapid urine test for beta human chorionic gonadotropin (β-HCG)~* Biochemical abnormalities as indicated by liver function tests, and/or creatinine \>1.5 times above upper limit of the normal range.~* Receiving any routine medications that may interfere with test drug metabolism that cannot be stopped one week prior to onset of study~* Evidence of urinary tract infection as indicated by an active urinary sediment (\>6- 8 pus/neutrophil cells per field) or 3+ nitrate on dipstick. Individuals without a gross active sediment 1 or 2 plus nitrate or with 1 + protein will not be excluded. Similarly individuals with 1+ haemoglobin on dipstick or trace amount of blood in the will not be excluded.~* Lactose and/or gluten intolerance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Single IDA dose W. bancrofti positive (Type: ACTIVE_COMPARATOR): Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) W. bancrofti infections positive
- Single IDA dose W. bancrofti negative (Type: ACTIVE_COMPARATOR): Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) in 40 individuals who are free of W. bancrofti infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Over-the-scope Clips and Standard Treatments in Endoscopic Control of Acute Bleeding From Non-variceal Upper GI Causes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with overt signs of acute upper GIB (melena, hematemesis, drop in hemoglobin with or without hypotension)~* documented bleeding lesions suitable for standard endoscopic treatment during endoscopy~Exclusion Criteria:~* without a full informed consent from the patient or his legally-acceptable representatives~* Age \<18 years~* Pregnant~* Lactating women~* Moribund patients not considered for active treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 111 Years
- Healthy Volunteers: f

Study Arms:
- Over-the-scope Clips (Type: EXPERIMENTAL): Endoscopic Application of Over-the-scope Clips
- standard treatment (Type: ACTIVE_COMPARATOR): standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine \<=20 clips or pulse

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 8 to 22 years old~* Diagnosed with RAP as verified by a physician, and having at least twice weekly episodes of abdominal pain which cause the patient to withdraw from normal activities.~* At least one month trial on a high fiber diet without resolution of abdominal pain.~* Ambulatory~Exclusion Criteria:~* Focal abdominal pain by history or physical exam, unless a negative (including endoscopic) evaluation has been performed~* Current diagnosis of inflammatory bowel disease, pancreatitis (acute or recurrent), peptic ulcer disease, gastrointestinal infection (unresolved), or ongoing gastrointestinal inflammation.~* Current or recent (within the past year) pregnancy and/or current breastfeeding.~* Current diagnosis of nephropathy or genitourinary disease.~* Blood in stools or emesis (EXCEPTION: blood in the stool secondary to hemorrhoids is not an exclusion criterion).~* Unintentional loss of over 10% body weight over the past 3 months or weight \< 100% ideal body weight.~* Recurrent fevers (T\>100F) at least once a week or with abdominal pain episodes.~* Recurrent dehydration with abdominal pain episodes requiring intravenous rehydration.~* Current personal diagnosis of depression or report of suicidality, mania or bipolar disorder.~* Family history of mania or bipolar disorder.~* Current use of opiates or other prescription pain medications and/or refusal to remain off opiate/prescription pain medications during the study period.~* Currently receiving additional therapies besides diet for recurrent abdominal pain and/or refusal to remain off such therapies during the study period, including but not limited to anticholinergic medications, antidepressant medications, biofeedback therapy, cognitive behavioral therapy.~* Hypersensitivity to SAM-e.~* Inability of child to provide assent and/or inability of parent/custodian to give consent.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): This an open-labeled study. All participants will be part of the treatment group and receive SAM-e. S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed informed consent prior to any study specific procedures~* Female or male aged ≥18 years at the time of consent~* eGFR ≥25 and ≤75 mL/min/1.73m2 (CKD-EPI Formula) at visit 1~* Evidence of increased albuminuria 3 months or more before visit 1 and UACR ≥200 and ≤5000 mg/g at visit 1~* Stable, and for the patient maximum tolerated labelled daily dose, treatment with ACE-I or ARB for at least 4 weeks before visit 1, if not medically contraindicated,~Exclusion Criteria:~* Autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or ANCA-associated vasculitis~* Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment~* History of organ transplantation~* Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor~* Type 1 diabetes mellitus~* New York Heart Association (NYHA) class IV Congestive Heart Failure at the time of enrolment~* MI, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): Patients will be randomized 1:1 to either dapagliflozin or placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching dapagliflozin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Oral Magnesium to Prevent Postoperative Atrial Fibrillation Following Coronary Surgery (POMAF-CS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients~* Coronary artery disease~* Planned coronary artery surgery~* signed informed consent~Exclusion Criteria:~* Preoperative supraventricular dysrhythmia including atrial fibrillation, either acute or chronic~* Left ventricular EF \< 30%~* Urgent surgery~* Redo surgery~* Permanent preoperative pacemaker~* Preoperative anti arrythmia drugs classes I and III~* Post operative inotrope drugs~* Postoperative bradycardia necessitating electrosystolic pacing~* Preoperative heart rate less than 50 bpm~* documented preoperative dysthryroidism~* 2nd and 3rd degree atrioventricular bloc~* Renal failure with GFR \< 30 ml/min/1.73 m²

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Preoperative oral Magnesium (Type: EXPERIMENTAL): Magnesium sulfate 8 tablets (8 x 0.4 g) per day, PO, for the 3 days preceding the surgical intervention
- Control (Type: PLACEBO_COMPARATOR): Placebo oral tablet, for Magnesium Sulfate tablets, PO, for the 3 days preceding the surgical intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Osteoporosis as defined by very low bone mineral density in the hip and spine or low bone mineral density in the hip combined with presence of 1-3 mild or moderate fractures of the vertebrae~Exclusion Criteria:~* Low Vitamin D~* Renal insufficiency~* Previous treatment with certain anti-osteoporotic therapies (except after certain washout periods): calcitonin, bisphosphonates, parathyroid hormone (PTH), sodium fluoride, strontium ranelate,~* Previous treatment with testosterone, anabolic steroids or growth hormone~* Chronic use of systemic corticosteroids (oral or i.v.) within the last year~* History of any cancer or metastases within the last 5 years~* History of brittle bone disease, multiple myeloma, or Paget's disease, or any other metabolic bone disease, except osteoporosis~* Bilateral hip replacements~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid (Type: EXPERIMENTAL): 5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
- Placebo (Type: PLACEBO_COMPARATOR): 100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The i.v. infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Nalmefene in Patients With Alcohol Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~In- and outpatients who:~* had a primary diagnosis of alcohol dependence according to Diagnostic and Statistical Manual of Mental Disorders - Text revision (DSM-IV-TR) criteria~* had had ≥6 HDDs in the 4 weeks preceding the Screening Visit~* had had an average alcohol consumption at WHO medium risk level or above in the 4 weeks preceding the Screening Visit~Exclusion Criteria:~The patient:~* had a DSM-IV Axis I disorder other than alcohol dependence or nicotine dependence~* had an antisocial personality disorder~* had risk of suicide evaluated by the suicidality module of the Mini-International Neuropsychiatric Interview (MINI)~* had a history of delirium tremens or alcohol withdrawal seizures~* reported current or recent (within 3 months preceding screening) treatment with disulfiram, acamprosate, topiramate, naltrexone or carbimide, or with any opioid antagonists~* reported current or recent treatment with antipsychotics or antidepressants~* was pregnant or breast-feeding~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Nalmefene (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: In-vivo Efficacy of Patient Preoperative Prep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects of any race~* Subjects in good health~* Minimum skin flora baseline requirements on abdomen and groin~* Skin free of tattoos, dermatoses, abrasions, cuts, lesions, or other skin disorder near or on the applicable test area.~Exclusion Criteria:~* Topical or systemic antimicrobial exposure within 14 days prior to screening and treatment days, including antibiotics.~* Subjects with a history of skin sensitivity, skin allergies, or skin cancer.~* Subjects who are pregnant, attempting pregnancy or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ZP (70% IPA) (Type: EXPERIMENTAL): Isopropyl alcohol (IPA) 70%
- ChloraPrep (Type: ACTIVE_COMPARATOR): Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
- ZP Vehicle (Type: PLACEBO_COMPARATOR): ZP without IPA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Continuous non smoker who has not used nicotine containing products for at least 20 years prior to the first dosing and throughout the study, based on subject self-reporting.~2. Body mass index greater than or equal to (\>=)18 and less than (˂) 30.0 kilogram per square meter (kg/m\^2) at screening.~Exclusion Criteria:~1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.~2. Has history or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.~3. Has positive urine drug or alcohol results at screening or first check in.~4. Estimated creatinine clearance \< 80 milliliter per minute (mL/min) at screening.~5. Has tattoo(s) or scarring at or near the site of intravenous (IV) infusion or any other condition which may interfere with infusion site examination, in the opinion of the investigator.~6. Has infrequent bowel movements (less than approximately once per day) within 30 days prior to first dosing.~7. Has recent history of abnormal bowel movements, such as diarrhea, loose stools, or constipation, within 2 weeks of first dosing.~8. Has received radiolabeled substances or has been exposed to radiation sources within 12 months of first dosing or is likely to receive radiation exposure or radioisotopes within 12 months of first dosing such that participation in this study would increase their total exposure beyond the recommended levels considered safe (that is., weighted annual limit recommended by the Commission on Radiological Protection \[ICRP\] of 3000 millirem).~9. Donation of blood or significant blood loss within 56 days prior to the first dosing.~10. Plasma donation within 7 days prior to the first dosing.

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Mobocertinib 160 mg and [14C]-Mobocertinib 50 mcg + [14C]-Mobocertinib 160 mg (Type: EXPERIMENTAL): Mobocertinib 160 mg, capsule, orally, once under fasted state, followed by \[14C\]-mobocertinib 50 mcg (approximately 2 microcurie \[mcCi\]), infusion, intravenously, once on Day 1 of Period 1, further followed by a washout period of 9 days, followed by \[14C\]-mobocertinib 160 mg (approximately 100 mcCi), solution, orally, once under fasted state on Day 1 of Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete